Latest News about LGVN
Recent news which mentions LGVN
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™
December 05, 2023
Tickers
LGVN
From Benzinga
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™
December 05, 2023
Tickers
LGVN
From Benzinga
Earnings Scheduled For November 10, 2023
November 10, 2023
From Benzinga
Nearly A Third Of Japan's 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron's (NASDAQ: LGVN) Cell Therapy Help?
October 23, 2023
Tickers
LGVN
From Benzinga
Does Bone Marrow Contain The Keys To Curing Alzheimer's? BioTech Announces Promising Results From Clinical Trial
October 13, 2023
Tickers
LGVN
From Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 12, 2023
From Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
October 09, 2023
From Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 09, 2023
From Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 06, 2023
From Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
October 05, 2023
From Benzinga
Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
October 05, 2023
From Benzinga
Longeveron stock jumps on Alzheimer’s trial results
October 05, 2023
From MarketWatch
12 Health Care Stocks Moving In Friday's Pre-Market Session
September 15, 2023
From Benzinga
Roth MKM Analyst Projects An Impressive Price Target Of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says "Low Valuation Undeserved"
September 14, 2023
From Benzinga
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
September 11, 2023
From Benzinga
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
September 06, 2023
From Benzinga
Why Lands' End Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
August 31, 2023
From Benzinga
US Stocks Rise; Initial Jobless Claims Edge Lower
August 31, 2023
From Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
August 31, 2023
From Benzinga
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
August 29, 2023
From Benzinga
Earnings Scheduled For August 11, 2023
August 11, 2023
From Benzinga
Longeveron – This Biotech Company Is Using The Body's Own Cells To Fight Age-Related Diseases
August 07, 2023
Tickers
LGVN
From Benzinga
From Benzinga
Longeveron – Regenerative Medicine Developer Announces 100% Long Term Survival Rate For Children With HLHS
July 11, 2023
Tickers
LGVN
From Benzinga
From Benzinga
Tickers
LGVN
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.